Pharmacological features of mesoionic compounds: antitumoral effects and bioenergetic disruption of sydnones and 1,3,4-thiadiazolium derivatives.

Authors

André Felipe Naidek, Mariane Londero Rodrigues, Maria Carolina Stipp, Douglas de Jesus da Silva Claudino, Aurea Echevarria, Silvia Suter Correia Cadena, Alexandra Acco

Published in

Naunyn-Schmiedeberg's archives of pharmacology. Oct 10, 2026. Epub Oct 10, 2026.

Abstract

Mesoionic compounds are five-membered heterocyclic betaines that cannot be satisfactorily represented by a single covalent or polar structure. Because their positive and negative charges are delocalized over separate regions of the ring, they yield a net-neutral molecule with a high dipole moment. This unique electronic configuration confers amphiphilic character and pronounced affinity for biological membranes, including mitochondria, underlying a broad pharmacological profile that includes antitumoral, anti-inflammatory and analgesic activities. Among the several mesoionic scaffolds, sydnones (1,2,3-oxadiazolium-5-olate) and 1,3,4-thiadiazolium derivatives have been the most extensively studied, drawing particular attention to their pronounced antineoplastic activity against melanoma, hepatocellular carcinoma, breast cancer and glioblastoma models. Their anticancer effects are closely linked to mitochondrial bioenergetic disruption, including uncoupling of oxidative phosphorylation, inhibition of respiratory complexes, dissipation of the mitochondrial membrane potential, and stimulation of F1Fo-ATPase activity, which together cause ATP depletion, redox imbalance, and apoptosis induction. This review provides a comprehensive analysis of the structural features that govern these biological properties, the antitumor efficacy of sydnones and thiadiazolium derivatives across various cancer models, and the underlying mitochondrial mechanisms. By integrating chemical, pharmacological, and bioenergetic perspectives, this article highlights the potential of mesoionic compounds as versatile scaffolds for the anticancer drug development, emphasizing their preclinical antitumoral activities, the mechanisms related to cell bioenergetics, and the challenges to improve the bioviability through nanotechnologies.

PMID:
42859209
Bibliographic data and abstract were imported from PubMed on 11 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.